478646-33-2

Basic information

• Product Name: (S)-3-N-CBZ-AMINO-PIPERIDINE
• Synonyms: (S)-benzyl piperidin-3-ylcarbamate;benzyl N-(piperidin-3-yl)carbaMate;(3S)-3-[(Benzyloxycarbonyl)amino]piperidine;Benzyl (S)-piperidin-3-ylcarbamate;N-(3S)-3-Piperidinylcarbamic acid phenylmethyl ester;(S)-3-(Cbz-aMino)piperidine;(S)-3-(Cbz-aMino)piperidi...;benzyl N-[(3S)-piperidin-3-yl]carbaMate
• CAS NO: 478646-33-2
• Molecular Formula: C₁₃H₁₈N₂O₂
• Molecular Weight: 234.3
• Mol File: 478646-33-2.mol

Chemical Properties

• Boiling Point: 396.3 °C at 760 mmHg
• Flash Point: 193.5 °C
• Appearance: /
• Density: 1.13
• Vapor Pressure: 1.73E-06mmHg at 25°C
• Refractive Index: 1.557
• Storage Temp.: 2-8°C(protect from light)
• PKA: 12.16±0.20(Predicted)
• CAS DataBase Reference: (S)-3-N-CBZ-AMINO-PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-3-N-CBZ-AMINO-PIPERIDINE(478646-33-2)
• EPA Substance Registry System: (S)-3-N-CBZ-AMINO-PIPERIDINE(478646-33-2)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-37
• Hazardous Substances Data: 478646-33-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(S)-3-N-Cbz-amino-piperidine is used as an intermediate in the synthesis of various pharmaceutical drugs. Its protective carbobenzyloxy group allows for controlled reactions, ensuring the selective formation of desired compounds without unwanted side reactions. This makes it a valuable component in the development of new medications.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (S)-3-N-Cbz-amino-piperidine serves as a key building block for the creation of novel drug candidates. Its piperidine ring structure is a common feature in many bioactive molecules, and the Cbz group provides a versatile platform for further chemical modifications, facilitating the exploration of new therapeutic agents with improved efficacy and safety profiles.

InChI:InChI=1/C13H18N2O2/c16-13(15-12-7-4-8-14-9-12)17-10-11-5-2-1-3-6-11/h1-3,5-6,12,14H,4,7-10H2,(H,15,16)/t12-/m0/s1

Upstream product

• 95582-17-5 (S)-3-[[(phenylmethoxy)carbonyl]amino]-2-oxopiperidine 
• 501-53-1 benzyl chloroformate 
• 1002360-09-9 tert-butyl (3S)-3-{[(benzyloxy)carbonyl]amino}piperidine-1-carboxylate 
• 625471-18-3 tert-butyl (3S)-3-aminopiperidine-1-carboxylate 

Downstream Products

• 1912445-55-6 (S)-4-(3-(but-2-ynamido)piperidin-1-yl)-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide 
• 927389-28-4 7-[(3S)-3-benzyloxycarbonylaminopiperidin-1-yl]-2-tert-butyl-5-methyl-6-phenyl-1,3-benzoxazole-4-carbonitrile 
• 1620240-06-3 C₃₉H₃₅N₇O₅ 
• 1620239-28-2 benzyl {(3S)-1-[3-({[3-{[(benzyloxy)carbonyl]amino}-7-(cyanomethyl)quinolin-2-yl]carbonyl}amino)pyridin-4-yl]piperidin-3-yl}carbamate 
• 1620240-05-2 benzyl [(3S)-1-(3-amino-5-cyanopyridin-4-yl)piperidin-3-yl]carbamate 
• 1620240-04-1 benzyl [(3S)-1-(3-cyano-5-nitropyridin-4-yl)piperidin-3-yl]carbamate 
• 1620239-13-5 benzyl [(3S)-1-(3-{[(3-{[(benzyloxy)carbonyl]amino}-7-bromoquinolin-2-yl)carbonyl]amino}pyridin-4-yl)piperidin-3-yl]carbamate 
• 1620239-10-2 benzyl [(3S)-1-(3-aminopyridin-4-yl)piperidin-3-yl]carbamate 
• 1620239-34-0 benzyl [(3S)-1-(3-{[(3-{[(benzyloxy)carbonyl]amino}-6-fluoro-7-vinylquinolin-2-yl)carbonyl]amino}pyridin-4-yl)piperidin-3-yl]carbamate 
• 1620240-03-0 benzyl [(3S)-1-(3-bromo-5-nitropyridin-4-yl)piperidin-3-yl]carbamate 
• 1620239-09-9 benzyl [(3S)-1-(3-nitropyridin-4-yl)piperidin-3-yl]carbamate 

Relevant articles and documents

INHIBITORS OF CYCLIN DEPENDNT KINASE 7 (CDK7)

The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

Synthesis and biological activity of sulphostin analogues, novel dipeptidyl peptidase IV inhibitors

The structure of sulphostin (1), a novel dipeptidyl peptidase IV (DPP-IV) inhibitor, is consisted of three key functional groups, including a characteristic amino(sulfoamino)phosphinyl group, on a piperidine ring. To examine the relationship between its s